Chronic lymphocytic leukaemia (CLL) is a cancer of the blood and bone marrow that most often affects older adults. CLL responds to bone marrow stem cell transplantation (allo-HSCT); however, the rate of relapse for CLL remains relatively high.
A benefit of allo-HSCT is that treatment can result in the development of an anti-tumor response produced by the grafted cells and is associated with a low risk of cancer relapse.
In this issue of the Journal of Clinical Investigation, Catherine Wu and colleagues at the Dana Farber Cancer Institute in Boston report the results of a clinical trial that tested the effectiveness of vaccination with a CLL patient's own leukemia cells in the development of anti-tumour responses and relapse reduction.
Patients with advanced CLL were vaccinated with their own irradiated tumour cells following allo-HSCT.
Nearly 3 years after vaccination, 13 of the 18 vaccinated patients were in complete remission.
The 6 patients that received the maximum vaccine dosage produced T cells that specifically reacted against tumours cells.
These results suggest that tumour cell vaccination has the potential to enhance anti-tumor responses following allo-HSCT.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.